Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 24;4(281):1000281.
doi: 10.4172/2161-0711.1000281.

Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives

Patricia Chalela  1 , Lucina Suarez  2 , Edgar Muñoz  1 , Kipling J Gallion  1 , Brad H Pollock  3 , Steven D Weitman  4 , Anand Karnad  4 , Amelie G Ramirez  1
Affiliations

Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives

Patricia Chalela et al. J Community Med Health Educ. .

Abstract

Background: Inclusion of minorities in clinical research is an essential step to develop novel cancer treatments, improve health care overall, understand potential differences in pharmacogenomics and address minorities' disproportionate cancer burden. However, Latinos and other minority groups continue to be critically underrepresented, particularly in early-phase clinical trials (EPCTs). The objective of the present study was to explore barriers and promoting factors influencing patients' decisions to enroll or not in early phase clinical trials (EPCTs) and identify areas for intervention to increase minority enrollment into clinical research.

Methods: An interviewer-administered survey was conducted with 100 cancer patients in the predominantly Latino region of South Texas. Exploratory factor analysis was conducted to identify underlying dimensions, and multiple logistic regression assessed significant factors that promote or deter patients enrollment to EPCTs. In addition, a separate subgroup mean analysis assessed differences by enrollment status and race/ethnicity.

Results: For one standard deviation increase in the importance given to the possibility of symptoms improvement, the predicted odds of refusing enrollment were 3.20 times greater (OR=3.20, 95% CI=1.06-9.71, p 0.040). Regarding barriers, among patients who considered fear/uncertainty of the new treatment a deterrent to enrollment, one standard deviation increase in agreement with these barriers was associated with a 3.60 increase (OR=3.60, 95% CI=1.30-9.97h, p 0.014) in the odds of not being enrolled in an EPCT. In contrast, non-enrolled patients were less likely (OR=0.14, 95% CI=0.05-0.44, p 0.001) to consider fatalistic beliefs as an important barrier.

Conclusion: This study, one of the first to identify South Texas patients' barriers to enroll in EPCTs, highlights potential focal areas to increase participation of both minority and non-minority patients in clinical research. Culturally tailored interventions promoting patient-centered care and bilingual, culturally competent study teams could solve common barriers and enhance Latinos' likelihood of joining clinical trials. These interventions may simultaneously increase opportunities to involve patients and physicians in clinical trials, while ensuring the benefits of participation are equitably distributed to all patients.

Keywords: Barriers; Cancer Patients; Clinical Trials; Early phase; Enrollment; Promoters.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Participant Recruitment Flow Chart
See this image and copyright information in PMC

References

    1. Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I, et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet. 2013;50:298–308. - PMC - PubMed
    1. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, et al. Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. J Clin Oncol. 2013;31:210–216. - PMC - PubMed
    1. Ford JG, Howerton MW, Bolen S, Gary TL, Lai GY, et al. Agency for Healthcare Research and Quality. Rockville, MD: 2005. Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. - PMC - PubMed
    1. Institute of Medicine. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, DC: National Academies Press; 1999. - PubMed
    1. Institute of Medicine. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. National Academies Press; 2010. - PubMed

LinkOut - more resources